Mirae Asset Global ETFs Holdings’s Celldex Therapeutics CLDX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.11M	Sell	35,339 -1,727	-5%	-$47.1K	﹤0.01%	1471
2025 Q4	$1M	Buy	37,066 +1,653	+5%	+$43.5K	﹤0.01%	1517
2025 Q3	$918K	Sell	35,413 -3,975	-10%	-$92.1K	﹤0.01%	1539
2025 Q2	$801K	Sell	39,388 -4,063	-9%	-$79.1K	﹤0.01%	1554
2025 Q1	$798K	Buy	43,451 +680	+2%	+$15.2K	﹤0.01%	1606
2024 Q4	$1.08M	Buy	42,771 +3,830	+10%	+$104K	﹤0.01%	1503
2024 Q3	$1.32M	Buy	38,941 +3,529	+10%	+$134K	﹤0.01%	1382
2024 Q2	$1.31M	Buy	+35,412	New	+$1.34M	﹤0.01%	1308

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CLDX Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Celldex Therapeutics (CLDX) stake by 4.7% in Q1 2026, selling an estimated $47.1K and leaving 35,339 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1471.

Mirae Asset Global ETFs Holdings first reported a position in CLDX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.32M in Q3 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

Mirae Asset Global ETFs Holdings held 35,339 shares of Celldex Therapeutics worth $1.11M as of Q1 2026.
Mirae Asset Global ETFs Holdings sold 1,727 Celldex Therapeutics shares in Q1 2026, an estimated $47.1K.
Celldex Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #1471 holding.
Mirae Asset Global ETFs Holdings first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 8 quarters since.
Mirae Asset Global ETFs Holdings's Celldex Therapeutics position peaked at $1.32M in Q3 2024.
228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.